Syntropharma is an emerging pharmaceutical company focussed on taking commercially successful generic compounds and improving their clinical profile by reformulating them as patch applications which are applied to the skin.
Its vision is to develop a stream of first and second to market transdermal products with strong IP that will be out licensed to pharmaceutical partners with commercial reach.
Syntropharma represents a new generation of forward thinking pharmaceutical companies creating innovative and well differentiated products utilising transdermal technology.
Reformulation for transdermal delivery remains underutilised. Syntropharma are convinced that their products offer real clinical advantages in the treatment of chronic illnesses.
Syntropharma work with a world class team of experts highly experienced in the development, registration and marketing of transdermal products.